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Edited by Maurice MontalAbstract Whole-cell patch-clamp recordings showed that a sub-
population (10%) of Jurkat cells, a model of human T-cells,
expressed a functional voltage-gated sodium channel, which was
tetrodotoxin (TTX)-resistant. Expression of voltage-gated so-
dium channel protein was conﬁrmed by western blots. Semi-
quantitative PCR analysis revealed that mRNAs for the
a-subunits of multiple voltage-gated sodium channel subtypes
were present but indicated that Nav1.5 was the predominant
subtype, consistent with the TTX-resistant nature of the recorded
currents. Importantly, 10 lM TTX reduced the number of
Jurkat cells invading a Matrigel basement membrane by
93.0% 5.5%. Since similar sodium channels have also been
detected in normal human T-lymphocytes, it is concluded that the
activity of voltage-gated sodium channels could represent a novel
mechanism potentiating the invasive capacity of these cells.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Eﬃcient functioning of the immune system depends on the
regulated traﬃcking of lymphocytes [1]. This ‘homing’ process
eventually targets immune eﬀector cells to tumours or to sites
of infection. Circulating lymphocytes are round, ‘non-motile’
cells, which redistribute their cytoskeletal elements and or-
ganelles to acquire a constantly changing shape and polarised
morphology during inﬂammatory response [2]. However, the
mechanism(s) controlling this response is not fully understood.
We have shown previously that cancer metastasis, a process
that involves a series of basic cellular behaviours, including
invasion, is controlled by voltage-gated Naþ channel (VGSC)
activity [3–10]. Accordingly, functional expression of VGSCs
could distinguish strongly and weakly metastatic prostate and
breast cancer cells [3–5,9,10], and blocking VGSC activity in
these cancer cells by application of tetrodotoxin (TTX) can
signiﬁcantly reduce their invasiveness in vitro [3–5,9,10].
Cells of the immune system traditionally have been cate-
gorised as ‘electrically inexcitable’, although most possess
voltage-dependent ion channels in their membranes, e.g., [11].* Corresponding author. Fax: +44-207-584-2056.
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molecular identity and functional role in these cells is not
known, e.g., [12]. The human T-cell leukaemia cell line ‘‘Jur-
kat’’ maintains functional characteristics of T-lymphocytes
and has been used widely as a model system, e.g., [13,14].
Voltage-gated Naþ channels are glycosylated transmem-
brane proteins that form pores in the cell membrane, permit-
ting inﬂux of Naþ down its ionic gradient in response to
membrane depolarisation. VGSCs are composed of a central
a-subunit (260 kDa) associated with accessory b-subunits
(33–36 kDa) that can modify channel properties and interact
with cytoskeletal and extracellular matrix proteins [15]. Most
VGSCs show sensitivity to nanomolar concentrations of TTX
and are thus classiﬁed as TTX-sensitive (TTX-S). However, a
subset of VGSCs shows sensitivity to TTX in the micromolar
range and is thus classiﬁed as TTX-resistant (TTX-R).
In the present study, using the Jurkat cell line, we investi-
gated (1) the molecular identity of the VGSCs expressed and
(2) whether VGSC activity could be involved in the cells’ in-
vasive behaviour.2. Materials and methods
2.1. Cell culture
Jurkat cells were grown and maintained in Roswell Park Memorial
Institute (RPMI) 1640 medium (Life Technologies Ltd, Paisley, UK)
supplemented with 4 mM L-glutamine, 100 lg/ml penicillin, 100 lg/ml
streptomycin and 10% foetal bovine serum (FBS). Cells were seeded into
100 mm Falcon tissue culture dishes (Becton Dickinson Ltd, Bedford,
UK) and grown in an incubator at 37 C, 100% humidity and 5% CO2.
2.2. Electrophysiology and pharmacology
The electrophysiological techniques used have been described in
detail previously [3,4,16]. Two basic command voltage protocols were
used with a holding potential of )100 mV: (1) Current–voltage (I–V)
protocol. This was used to study the voltage-dependence of VGSC
activation. Cells were pulsed to depolarising test potentials between
)70 and +70 mV, in 5 mV steps. The test pulse duration was 40 ms and
the interpulse period was 2 s. (2) Repeat single-pulse protocol. This was
used to monitor the eﬀects of TTX on current amplitude. Test pulses
were to )10 mV. The test pulse duration was 40 ms, the interpulse
duration was 10 s and there were 10 repeat pulses. TTX (Alomone
Labs Ltd, Jerusalem, Israel), was applied using a gravity-fed Y-tube
perfusion system. The eﬀect of TTX on the inward current was cal-
culated as the percentage block of current (B), as follows:
B ð%Þ ¼ ½1 ðIa=IbÞ  100, where Ib and Ia are the current amplitudes
recorded before and after TTX application, respectively.
2.3. RNA extraction and cDNA synthesis
Total cellular RNA was isolated from three separate batches of the
Jurkat cell line using a total RNA miniprep kit (Stratagene, La Jolla,ation of European Biochemical Societies.
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Fig. 1. Electrophysiological recordings from Jurkat cells. (A) Traces showing activation of an inward current by pulsing the cell from a holding
potential of )100 mV in 5 mV steps from )70 to +70 mV with an interpulse interval of 2 s. Only every other trace is shown for clarity. (B) A plot of
the current–voltage relationship for the inward currents recorded as detailed in (A). (C) Suppression of the inward current by (i) 200 nM and (ii) 2
lMTTX. The cell was pulsed from a holding potential of )100 to )10 mV for 30 ms with a repeat interval of 10 s. The eﬀect of TTX was recorded on
the ﬁfth pulse. (D) Partial dose–response curve to TTX over the concentration range 20 nM to 2 lM. Data points denote meanS.E. (nP 3). Cells
were pulsed as outlined in part (C). The intracellular pipette solution contained Csþ to block outward Kþ currents in all recordings shown.
192 S.P. Fraser et al. / FEBS Letters 569 (2004) 191–194CA, USA) according to the manufacturer’s instructions. RNA quality
was assessed by gel electrophoresis and its quantity determined by
spectrophotometric analysis. cDNA was synthesised as described
previously [17].
2.4. Semi-quantitative PCR
cDNA was ampliﬁed by PCR using oligonucleotide primers directed
against the TTX-R VGSCs Nav1.5, Nav1.8 and Nav1.9 and two other
VGSC subtypes, Nav1.6, Nav1.7, previously found to be expressed in
cancer/invasive cells [9,10,17]. NADH-cytochrome b5 reductase
(Hcytb5R), which is expressed at very similar levels in cells derived
from numerous tissue types [17,18], was used as the control amplicon.
The primer sequences and PCR conditions used have been described
previously [17]. To allow direct comparison of results obtained from
each cell line, all comparable sscDNA and PCR reactions were per-
formed simultaneously. ‘Blanks’, with no template added, were used as
controls. A kinetic observation approach was adopted such that an
aliquot of 5 ll from the 60 ll reaction was taken at the end of each
ampliﬁcation cycle, for eleven cycles, while reactions were held at 72
C. The ampliﬁcation cycle at which aliquots were ﬁrst taken diﬀered
depending on the VGSCa studied.
2.5. Western blotting
VGSC proteins were extracted and prepared according to the
manufacturer’s instructions (Upstate Biotechnology, Buckingham,
UK) and further details have been described previously [4]. The pri-mary antibody was a pan-VGSC (Upstate Biotechnology) and the
secondary a peroxidase-conjugated swine anti-rabbit immunoglobulin
(DAKO, Glostrup, Denmark). The amount of protein loaded has been
speciﬁed in the ﬁgure legend.
2.6. Matrigel invasion assay
Cell culture invasion chambers with an 8 lm pore size precoated
with Matrigel basement membrane matrix (BD Biosciences, Bedford
MA, USA) were rehydrated according to the manufacturer’s in-
structions. Jurkat cells were loaded at a density of 5 105 cells/ml and
100 lg/ml SDF-1a (Insight Biotechnology, Middlesex, UK) was used
as a chemoattractant [19]. The experiment was done both in the
presence and absence of 10 lM TTX and was repeated three times.
Invaded cells were quantiﬁed after 6 h by either (i) counting 20 ﬁelds
of view (at 200 magniﬁcation; Nikon TMS, Nikon Instruments
Inc., Melville, NY, USA) or (ii) counting cells in a Neubauer
hemocytometer.
2.7. Toxicity assay
The toxicity assay protocol has been described in detail previously,
e.g., [6]. Brieﬂy, the relative proportion of dead cells was determined by
trypan blue exclusion following a 24 h incubation with either normal
growth medium or with 10 lM TTX. The number of live vs. dead cells
was determined from 30 randomly chosen ﬁelds of view at 100 under
an inverted microscope (ID 03 Carl Zeiss Ltd, Welwyn Garden City,
UK). The experiments were repeated three times.
S.P. Fraser et al. / FEBS Letters 569 (2004) 191–194 1932.8. Data analysis
All quantitative data are presented in the text as means S.E. Sta-
tistical signiﬁcance was determined by Student’s t-test. Data were de-
termined to be normally distributed except the toxicity data, which
were transformed prior to statistical analysis.3. Results
3.1. Electrophysiology
Jurkat cells showed a mean resting potential of )31.6 1.9
mV (n ¼ 42) and membrane capacitance of 11.2 0.7 pF
(n ¼ 60). In 10% (n ¼ 13=126) of recorded cells, membrane
depolarisation evoked an inward current that reached a peak
within a few milliseconds and then inactivated fully (Fig. 1A).
This inward current was completely abolished when the extra-
cellular Naþ was replaced with cholineþ (not shown). The
maximum size of the inward current was )83 26 pA which
corresponded to a current density of 7.0 1.8 pA/pF (n ¼ 13).
A typical current–voltage (I–V ) relationship is shown in Fig. 1B.
The threshold for activation was around )50 mV. Currents
activated more rapidly with successive depolarising steps,
reaching a peak at around )20 mV. The inward currents were
suppressed by TTX in a dose-dependent manner (Fig. 1C). The
dose–response relationship suggested an IC50 of approximately
900 nM (Fig. 1D). Taken together, these results were consistent
with 10% of Jurkat cells expressing functional TTX-R VGSCs.
3.2. Western blot and SQT-PCR
Western blots using a pan-speciﬁc VGSC antibody detected
a band of 200 kDa, similar to VGSC proteins found inFig. 2. (A) Expression of voltage-gated Naþ channel a-subunits in
Jurkat cells studied by Western blot using a pan-speciﬁc Naþ channel
antibody (Upstate, Milton Keynes, UK). Lane (1) 40 lg Jurkat cell
membrane preparation; lane (2) 10 lg mouse heart; lane (3) 10 lg
mouse brain. The data are representative of three separate experiments.
(B) Semi-quantitative PCR gel images for (i) Nav1.5, (ii) Nav1.6, (iii)
Nav1.7 and (iv) Nav1.9 products ampliﬁed from Jurkat cells. Repre-
sentative PCR cycle numbers for given bands are indicated above the
gels. n denotes the mis-transcribed/exon-skipped form of Nav1.6.mouse heart, that expresses mainly Nav1.5, and brain
(Fig. 2A). Semi-quantitative PCRs (SQT-PCR) indicated ex-
pression of Nav1.5 (TTX-R) and Nav1.6 (TTX-S), and to a
much lesser extent, Nav1.7 (TTX-S) and Nav1.9 (TTX-R)
(Fig. 2B). However, Nav1.8 (TTX-R) expression could not be
detected using PCR primers known to successfully amplify this
VGSC type (not shown) [17]. Nav1.6 mRNA was present only
in neonatal and the mis-transcribed/exon-skipped truncated
forms, denoted by D (Fig. 2B), neither of which would form
functional Nav1.6. It was concluded that Nav1.5 was the main
VGSC expressed, consistent with the TTX-R nature of the
sodium currents recorded (Fig. 1D).
3.3. Invasion assays
To determine possible functional consequences of VGSC
activity, Matrigel invasion assays were performed. Under
control conditions, 8% of Jurkat cells were invasive, close to
the percentage of cells expressing electrophysiologically de-
tectable VGSCs. Following treatment with 10 lM TTX, in-
vasion decreased such that only 0.6% of the cells invaded the
Matrigel. Thus, TTX reduced Jurkat cell invasiveness by
93.0 5.5% (P < 0:001; n ¼ 3; Fig. 3). Equimolar TTX had noFig. 3. (A) Pictures showing typical ﬁelds of view of Jurkat cells fol-
lowing invasion through a Matrigel-coated chamber under control
conditions (i) and following treatment with 10 lM TTX (ii). (B) Ma-
trigel invasiveness by Jurkat cells under control conditions (dark bar)
and following treatment with 10 lM TTX (light bar). Data are pre-
sented normalised to control values of 100% and are the meanS.E.
of three independent experimental repeats. The asterisks (***) indicate
that the diﬀerence was statistically signiﬁcant (P < 0:001).
194 S.P. Fraser et al. / FEBS Letters 569 (2004) 191–194eﬀect on cell viability (99 0.1% cf. control value of 100%;
P > 0:05).4. Discussion
In the present study, we have shown that Jurkat cells express
TTX-R VGSCs that potentiate the cells’ invasiveness. Of the
three TTX-R VGSCas (Nav1.5, Nav1.8 and Nav1.9) SQT-
PCR studies revealed that only Nav1.5 was expressed at ap-
preciable levels in the Jurkat cells. In contrast, Nav1.8 was not
detectable whilst Nav1.9 was expressed at low levels. SQT-
PCR studies also indicated that two TTX-S VGSCa (Nav1.6
and Nav1.7) mRNAs were expressed. However, rather than
adult Nav1.6, this subtype was present in two alternative splice
forms, which would not form functional Nav1.6 [20]. Thus,
this channel would not contribute to any functional VGSC
activity. Taken together, the SQT-PCR data with the TTX
pharmacology (IC50 900 nM) and electrophysiology, would
suggest that the inward current recorded was due mainly to
Nav1.5 and, to a much lesser extent, Nav1.7 expression. In-
terestingly, since we detected functional VGSCs in only 10% of
Jurkat cells, VGSC expression would appear to be under tight
control. Indeed, VGSC expression is highly dynamic and
regulated through numerous signal transduction pathways and
transcription factors (reviewed in [21]).
The Matrigel assays demonstrated that TTX signiﬁcantly
blocked invasiveness of the Jurkat cells by about 93%. As TTX
is a highly speciﬁc blocker of VGSCs, and invasion was re-
duced dramatically, it would follow that VGSC activity would
normally potentiate Jurkat cell invasion. Although, the precise
mechanism(s) through which the VGSCs could regulate cel-
lular invasiveness is not yet known, several possibilities can be
considered. Speciﬁcally, it has recently been reported that Naþ
inﬂux through VGSCs can regulate cell volume in Jurkat cells
[22] and changes in ion ﬂux and cell volume may be integral to
the invasion process, e.g., [23]. Furthermore, VGSC activity is
known to potentiate other cellular behaviours linked to inva-
sion, including secretion [7], adhesion [24] and motility [6,8,25].
In turn, the subcellular/molecular mechanisms underlying
these eﬀects may involve the cytoskeleton (directly via b-sub-
unit interaction and/or indirectly via local Ca2þ ﬂuxes), protein
kinase activity and gene expression [6,25].
In summary, our results demonstrated that Jurkat cells ex-
press a functional TTX-R VGSC, activity of which enhances
the invasiveness of these cells. As the Jurkat cell is a widely
accepted model for T-lymphocyte behaviour, it is tempting to
speculate that VGSCs may play an important role in the in-
vasive properties of normal human T-lymphocytes (which also
express functional VGSCs [12,26]) necessary to their intra-/
extra-vasation and inﬂammatory response. Other ‘normal’
cells (e.g., ﬁbroblasts and endothelial cells) capable of invasive
behaviour also have functional VGSCs [27,28]. Additionally,
several diﬀerent cancers (prostate, breast, small-cell lung car-
cinoma, neuronal tumours) express functional VGSCs
[3,4,9,10,29,30] that have been shown to potentiate cell inva-
sion in prostate and breast cancer cell lines [3–5,9,10]. Inter-
estingly, parallels have been drawn between lymphocyte
traﬃcking and cancer metastasis [31,32]. In overall conclusion,
therefore, VGSC expression/activity may represent a general
mechanism for potentiating cellular invasion under both nor-
mal and pathophysiological conditions.Acknowledgements: This work was supported, in part, by a Welcome
Trust PhD studentship (LJL). FP was supported by the Pro Cancer
Research Fund (PCRF).References
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